原发性肝癌微小RNA的研究进展.pdfVIP

Advances in Clinical Medicine 临床医学进展, 2018, 8(10), 963-967 Published Online December 2018 in Hans. /journal/acm /10.12677/acm.2018.810160 Advances in the Study of Micro-RNA in Primary Liver Cancer Hongjing Liu, Jiang Feng, Jianjun Yang Yan’an University Affiliated Hospital, Yan’an Shaanxi th th st Received: Nov. 30 , 2018; accepted: Dec. 14 , 2018; published: Dec. 21 , 2018 Abstract Primary hepatic carcinoma is one of the most common malignant tumors in clinical practice. Due to its insidious and rapid occurrence and development, most patients are in the middle and late stage at the time of diagnosis, resulting in high mortality. Therefore, it is very important to im- prove the early diagnosis rate of primary hepatic carcinoma. Currently, alphafetoprotein (AFP) has become a recognized serum marker for liver cancer screening and diagnosis, but in recent years, the number of primary hepatic carcinoma patients with AFP negative has been found to be increasing. In addition, a high rate of missed diagnosis of AFP was found in clinical work. There- fore, the search for specific molecules with good specificity and high sensitivity has been the di- rection of liver cancer researchers. At present, the role of microrna (miRNA) in tumorigenesis and development has become a research hotspot in the biomedical field, and the imbalance of miRNA expression is significantly correlated with the occurrence of multiple tumors. Among them, miR-122 and miR-21 are highly specifically expressed in liver. This paper reviews the current stu- dies on the specific manifestations of miR122 and miR-21 in primary liver cancer. Keywords Primary Hepatic Carcinoma, Microrn